8.27.2024
On December 8, 2023, the U.S. Food and Drug Administration approved two cell-based gene therapies for sickle cell disease (SCD), including one that utilizes CRISPR technology — the first of its kind to be approved. Despite the intention of this demonstrating a commitment from the medical community ...
Read Article